Integral Health Asset Management LLC Invests $8.55 Million in IQVIA Holdings Inc. $IQV

Integral Health Asset Management LLC purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 45,000 shares of the medical research company’s stock, valued at approximately $8,547,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Physician Wealth Advisors Inc. boosted its holdings in IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the last quarter. Westside Investment Management Inc. increased its holdings in shares of IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the last quarter. Atlantic Union Bankshares Corp purchased a new stake in shares of IQVIA during the 3rd quarter valued at approximately $36,000. Asset Dedication LLC lifted its holdings in IQVIA by 224.0% in the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 168 shares during the last quarter. Finally, Rothschild Investment LLC grew its position in IQVIA by 85.5% in the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after acquiring an additional 124 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on IQV. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and raised their target price for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Morgan Stanley set a $240.00 price target on IQVIA in a report on Wednesday, February 11th. Citigroup reduced their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. UBS Group decreased their target price on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Finally, Evercore reiterated an “outperform” rating and set a $225.00 price target on shares of IQVIA in a research report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $229.13.

IQVIA Price Performance

IQV stock opened at $164.78 on Friday. The business’s fifty day moving average price is $201.58 and its 200 day moving average price is $206.67. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. The company has a market capitalization of $27.96 billion, a PE ratio of 20.96, a P/E/G ratio of 1.57 and a beta of 1.39.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.IQVIA’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the business posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.